Blood test may let transplant patients stop virus meds earlier
NCT ID NCT06639854
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether stem cell transplant patients can safely stop taking a medicine called letermovir earlier if their immune system shows a strong response to CMV. About 105 participants will be monitored to see if this approach reduces infections and side effects compared to taking the medicine daily. The goal is to personalize treatment and improve recovery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS CELL MEDIATED IMMUNITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple video and kit program help kids take their transplant meds?
- Blood test could tailor CMV prevention after stem cell transplants
- Can 'Supercharged' donor cells beat viruses that drugs Can't?
- Banked immune cells show promise against Life-Threatening viruses in transplant patients
- Donor immune cells take on tough viruses in transplant patients
- Can a cancer drug wake up immune cells to beat HIV-Related infections?